SERVICE HOMEPAGESERVICE HOMEPAGE
European Bladder Cancer Therapeutics Markets
Deliverable Type: Market Research
Date Published: 14 Aug 2007
FEATURES OF THE RESEARCH VIEW BROCHUREVIEW BROCHURE  
Research OverviewResearch Overview TechnologiesTechnologies
Market OverviewMarket Overview List of FiguresList of Figures
Extended TOC Extended TOC Market SectorsMarket Sectors
Market Overview

Incapacity of Existing Bladder Cancer Therapies to Improve Long-term Patient Survival Rates Create Need for Superior Treatment Methods

Despite aggressive therapy with curative intent, muscle-invasive diseases continue to be responsible for patient mortality. The failure of several developments to improve the long-term survival rate of patients with bladder cancer is creating the need for new and advanced treatment methods. "As five-year survival rates in patients receiving conventional systemic therapy for metastatic disease are poor, there is a huge unmet need for novel treatments that improve survival or increase the therapeutic ratio of systemic therapy," explains the analyst of this research service. Moreover, no new drugs for bladder cancer have entered the market in two decades, which encourages the scope for novel treatments in the market.

Emerging treatment options include new cytotoxic drugs, new targeted therapies and new biological treatments, which include gene therapy. If these treatment options can offer greater clinical efficacy compared to existing treatments, it will drive the market immensely. Novel forms of therapy are much needed for patients with metastatic disease in particular, since the current treatment is only chemotherapy and/or radiotherapy.

Market Participants Must Explore New Areas of Drug Development and Delivery to Offset Impact of Mature Product Lines

Since chemotherapy and immunotherapy treatments have been in the market for decades, they have become heavily dominated by generics and this in turn has limited growth potential. "Companies developing drugs such as cisplatin, doxorubicin and methotrexate need to explore new areas of development and different ways to grow," notes the analyst. "This can extend treatment opportunities, patient groups and could help deliver the drug more effectively."

The strategic aim in the mature stage of the product life cycle is to win over customers from competitors and increase usage by offering value-added features such as the drug delivery mechanism. Research is being carried out to improve the outcomes of Mitomycin and Bacillus Calmette-Guerin (BCG) through different delivery mechanisms such as electromotive (intravesical electric current) drug delivery.

/
BACK TO TOP BACK TO TOP

QUICK SEARCH

GOGO
ADVANCED SEARCH
Search our research by date, market, technology, region or keywords
GO GO
SHARE
Discover how we can help your business
GO  GO
Learn how we can provide data and insight for your specific requirements
GO  GO
HELP DESK
For general assistance and enquiries:
Africa:
+27 21 680 3260
enquiries@frost.com

Asia Pacific:
+65 68900999
apacfrost@frost.com

Europe:
+44 (0)20 8996 8500
enquiries@frost.com

Israel:
+972-9-9502888
Israel@frost.com

Latin America:
+54 11 4777 1550
myfrost@frost.com

Middle East & North Africa:
+971.4.4331.893
meenquiries@frost.com

North America:
+1.877.463.7678
myfrost@frost.com

South Asia:
+91 (0) 22 6160 6666
saenquiries@frost.com

For a full list of our offices click here
Sitemap | Disclaimer | Privacy
© Frost & Sullivan
Conseq